Table 3. Safeguarding strategies in pluripotent stem cells.
| Vector | Promoter | Suicide gene | Cell types | Function | Reference |
|---|---|---|---|---|---|
| Non-viral plasmid |
PGK |
HSV-TK |
hESCs |
Ablation of teratomas |
43 |
| Lentivirus |
Ubiquitin C |
HSV-TK |
mESCs |
Prevention of teratoma formation |
42 |
| Lentivirus |
CMV |
HSV-TK |
mESCs |
Ablation of teratoma formation |
41 |
| Knock-in at the endogenous locus of OCT4 |
OCT4 |
HSV-TK |
mESCs |
Prevention of teratoma formation in spheroids culture |
46 |
| Non-viral plasmid |
OCT4 |
HSV-TK |
mESCs |
Prevention of teratoma formation |
47 |
| SSEA5 |
NA |
Anti-SSEA5 antibody |
hESCs/hiPSCs |
Prevention of teratoma formation |
44 |
| Lentivirus |
SFFV |
CD/ iCaspase9 |
Macaca nemestrina iPS cells |
Prevention and ablation of teratoma formation |
51 |
| Non-viral plasmid |
mifepristone-inducible promoter (GAL4 UAS) |
Caspase-1 |
mESCs |
Ablation of teratoma formation |
45 |
| Knock-in at the endogenous locus of Nanog |
Nanog |
Enhanced mutant version of HSV-TK |
hESCs |
Prevention of teratoma formation |
50 |
| Lentivirus | EF1a/Nanog | DeltaTK/CD | hESCs/hiPSCs mECSs/miPSCs |
Prevention and ablation of teratoma formation | 52, 53 |